Bovine acute mastitis: effects of intravenous sodium salicylate on endotoxin-induced intramammary inflammation.
Effects of the nonsteroidal antiinflammatory agent sodium salicylate on endotoxin-induced mastitis were evaluated in lactating cows. Escherichia coli endotoxin was administered to a mammary quarter 1 h after initiation of a 12-h i.v. infusion of sodium salicylate. Milk SCC, BSA concentrations in milk, mammary inflammation, rectal temperature, appetite, milk production, and plasma and lymph PGF2 alpha were monitored. Gross mammary inflammation was not reduced by salicylate infusion, nor did sodium salicylate prevent increased milk SCC or BSA concentrations in milk, although treatment tended to decrease the magnitude of these responses. Sodium salicylate decreased subcutaneous abdominal vein PGF2 alpha metabolite, and PGF2 alpha metabolite tended to be reduced in lymph during the acute phase of inflammation. The increased rectal temperature after endotoxin infusion was reduced in cows treated with sodium salicylate. Appetite was reduced after endotoxin infusion in untreated cows and those treated with sodium salicylate. Milk production declined after endotoxin challenge in all cows. Although sodium salicylate did not substantially reduce mammary inflammation, it had an antipyretic effect and reduced PGF2 alpha metabolite in mammary blood.
Morkoç
A C
AC
Department of Animal Sciences, University of Illinois, Urbana 61801.
Hurley
W L
WL
Whitmore
H L
HL
Gustafsson
B K
BK
D000818:Animals; D002417:Cattle; D015237:Dinoprost / Q000097:blood / Q000378:metabolism; D004731:Endotoxins; D004926:Escherichia coli; D005260:Female; D007262:Infusions, Intravenous; D007774:Lactation; D008196:Lymph / Q000378:metabolism; D008414:Mastitis, Bovine / Q000139:chemically induced / Q000188:drug therapy* / Q000503:physiopathology; D012980:Sodium Salicylate / Q000008:administration & dosage / Q000097:blood / Q000627:therapeutic use*
D004731:Endotoxins; D015237:Dinoprost; D012980:Sodium Salicylate